To explore the efficacy of rituximab as an adjuvant to GDP in the treatment of non-Hodgkin lymphoma(NHL) and its effect on thymidine kinase(TK)-1, recombinant factor related apoptosis ligand(FASL) and platelet-derived growth factor(PDGF)-BB.
A total of 210 NHL patients who were treated in our hospital from September 2021 to September 2024 were selected and randomly divided into the observation group and the control group,with 105 cases in each group. The control group was given the GDP regimen, while the observation group was added with rituximab. The clinical efficacy, TK-1, FASL, PDGF-BB, changes of peripheral blood T lymphocyte subsets, cluster of differentiation(CD)8+, CD4+ and CD3+ of the two groups were compared to evaluate the quality of life and occurrence of adverse reactions of the patients.
A total of 103 cases in the observation group and 101 cases in the control group completed the study. After treatment, the disease control rate of the observation group was higher than that of the control group(72.82% vs. 58.42%, P<0.05). The levels of TK-1, FASL and PDGF-BB in both groups were lower than those before treatment(P<0.05), and those in the observation group were lower than those in the control group(P<0.05). The CD8+ level in both groups was lower than that before treatment(P<0.05), and the level in the observation group was lower than that in the control group(P<0.05). The levels of CD4+ and CD3+ were increased before treatment, and the levels in the observation group were higher than those in the control group(P<0.05). The scores of physical function,emotional function, social function, cognitive function and role function of the two groups of patients were significantly higher, and the observation group was higher than the control group(P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups of patients(P>0.05).
Among NHL patients, the rituximab adjuvant GDP regimen has a better therapeutic effect and can effectively improve the levels of TK-1, FASL and PDGF-BB.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |